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Summary
Background Policies for early detection of breast cancer, including clinical breast examinations and mammographic 
screening, were introduced in Brazil in 2004, but their effect on disease stage at diagnosis is unclear. We aimed to 
assess whether these policies have led to a decrease in the prevalence of late-stage breast cancer at diagnosis. 
Methods In this case only analysis, using an anonymised nationwide hospital based-cancer registry network, we 
identified women aged 18–89 years who had been diagnosed with an invasive breast cancer in Brazil during 2001–14. 
We extracted individual patient-level data on patient demographics, tumour variables, and health-care provider 
variables for the centre where the patient was diagnosed. Our objectives were to estimate the prevalence of late-stage 
breast cancer (TNM stage III or IV) at diagnosis overall, across age groups, and by ethnoracial and social strata 
(ie, self-reported ethnoracial group, as white, black, brown, Asian, or Indigenous, and educational level, marital 
status, and region of residence) across the study period, and compare these estimates with international data from 
high-income countries (Norway and the USA). We used logistic regression to estimate odds ratios (ORs) for late-stage 
versus early-stage (TNM stage I or II) breast cancer at diagnosis in relation to relevant exposures, either minimally 
adjusted (for age, year of diagnosis, and region of residence) or fully adjusted (for all patient, tumour, and health-care 
provider variables).
Findings We identified 247 719 women who were diagnosed with invasive breast cancer between Jan 1, 2001, and 
Dec 31, 2014, with a mean age at diagnosis of 55·4 years (SD 13·3), of whom 36·2% (n=89 550) identified as white, 
29·8% (n=73 826) as black or brown, and 0·7% (n=1639) as Asian or Indigenous. Prevalence of late-stage breast 
cancer at diagnosis remained high throughout 2001–14, at approximately 40%, was inversely associated with 
educational level (p value for linear trend <0·0001), and was higher for women who identified as black (minimally 
adjusted OR 1·61, 95% CI 1·53–1·70; fully adjusted OR 1·45, 95% CI 1·38–1·54) and brown (minimally adjusted OR 
1·26, 95% CI 1·22–1·30; fully adjusted OR 1·18, 1·14–1·23) than those who identified as white. The predicted 
prevalence of late-stage cancer at diagnosis was highest for women who were black or brown with little or no formal 
education (48·8%, 95% CI 48·2–49·5) and lowest for women who were white with university education (29·4%, 
28·2–30·6), but both these prevalences were higher than that of all women diagnosed with breast cancer in Norway 
before the introduction of mammography screening (ie, 16·3%, 95% CI 15·4%–17·2% in 1970–74). Similar 
ethnoracial and social patterns emerged in analyses restricted to the age group targeted by screening (50–69 years). 
Interpretation The persistently high prevalence of late-stage breast cancer at diagnosis across all ethnoracial and social 
strata in Brazil, although more substantially among the most disadvantaged populations, implies that early detection 
policies might have had little effect on breast cancer mortality so far, and highlights the need to focus primarily on 
timely diagnosis of symptomatic breast cancer rather than on screening for asymptomatic disease.
Funding Newton Fund, Research Councils UK, and Conselho Nacional das Fundações Estaduais de Amparo à 
Pesquisa.
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Introduction
Incidence of breast cancer in Brazil, an upper-middle-
income country, has been increasing in the past decade, 
as in most other low-income and middle-income 
countries, reflecting population ageing and adoption of 
reproductive (eg, delayed age at first birth and fewer 
children than in previous generations) and lifestyle 
(eg, that lead to excess weight at postmenopausal 
ages) behaviours associated with an increased risk of 
developing the disease. Although in cidence of the disease 
is still considerably lower in these countries than in most 
high-income coun tries (age-adjusted incidence: 59·5 per 
100 000 women in Brazil vs 92·9 per 100 000 in the USA 
and 73·1 per 100 000 in Norway),1 mortality due to the 
disease is as high in Brazil as in many high-income 
countries (14·3 per 100 000 women in Brazil vs 14·9 per 
100 000 in the USA and 12·5 per 100 000 in Norway),1 
with mortality having increased across all age groups 
since 1979, contrasting substantially with decreases seen 
in most high-income countries since the early 1990s.2
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Breast cancer is a potentially curable disease if 
diagnosed at an early stage. Advanced stage at diagnosis 
is difficult and costly to treat, and is associated with 
increased morbidity and poor survival in high-income 
countries3,4 and in Brazil.5 Thus, a potential reason for the 
dis proportionately high breast cancer mortality in Brazil 
is diagnosis at a late-stage.
A shift towards diagnosing breast cancer at an early 
stage is a necessary, but not sufficient, prerequisite for 
decreasing mortality from the disease. This shift can be 
achieved through downstaging (also known as stage 
migration—ie, by ensuring that symptomatic women 
are diagnosed and treated at an early stage) or through 
screening to detect asymptomatic disease. These two 
approaches are interconnected because the capability of 
a country’s health system to appropriately manage 
symptomatic disease is a pre requisite to the intro-
duction of an effective screening programme, since a 
health system that struggles to cope with symptomatic 
disease will be unable to deal with the additional burden 
of screen-detected suspicious lesions and subsequently 
confirmed asymptomatic cases. Nevertheless, early 
detection policies in Brazil, as in many low-income and 
middle-income countries, have tried to emulate those 
being currently implemented in high-income countries 
by focusing mainly on screening, with the Brazilian 
Ministry of Health recom mending biennial mammo-
graphic screening for women aged 50–69 years 
since April, 2004.6 Promotion of breast cancer awareness 
and annual clinical breast examinations for women 
aged 40 years and older were also recommended but 
received less attention.
Ethnoracial and social disparities in early detection of 
and survival from breast cancer have been documented 
in many countries.3,7–10 Despite decreases in economic 
disparity in the past decade, Brazil still ranks among the 
countries with the highest levels of income inequality,11 
with its population comprising several ethnoracial 
groups. Although studies have examined the prevalence 
of late-stage breast cancer at diagnosis and its 
correlates,5,12,13 none to our know ledge have focused on 
patterns across ethnoracial and social strata.
We aimed to use data from a nationwide network of 
hospital-based cancer registries in Brazil, covering 
14 years from 2001 to 2014, to investigate whether the 
policies of early breast cancer detection introduced 
Research in context
Evidence before this study
Incidence of breast cancer in Brazil has been increasing due to 
population ageing and adoption of risky lifestyles, and is 
expected to almost double by 2035. Early detection policies, 
with a focus on mammographic screening, but also including 
promotion of breast cancer awareness and annual clinical 
breast examinations for women aged 40 years and older, were 
introduced in 2004 by the Brazilian Government, but whether 
these policies are associated with a shift towards early-stage 
disease at diagnosis is unknown. We searched PubMed using no 
language or date restrictions on July 9, 2018, using the terms 
(breast cancer* OR breast neoplasm* OR breast carcinoma* OR 
breast sarcoma* OR breast tumor* OR breast tumour* OR 
breast malignanc*) AND (stage* OR clinical feature*) AND 
Brazil. We identified 298 publications and screened their titles 
and abstracts, and if relevant also their full text. A few papers 
had previously examined stage of breast cancer at diagnosis in 
Brazil, but none had specifically focused on assessing whether 
the 2004 control policies were associated with a decrease in the 
prevalence of late-stage disease at diagnosis across the various 
ethnoracial and social strata in Brazil.
Added value of this study
This study showed that the prevalence of late-stage breast 
cancer at diagnosis, at all ages and in the target screening age 
group (age 50–69 years), remained high at approximately 
40% throughout 2001–14. Persistent ethnoracial and social 
differences were observed, with black and brown women with 
little or no formal education having the highest prevalence of 
late-stage disease at diagnosis and white women who were 
university educated having the lowest prevalence. However, 
white women who were university educated still had a 
substantially higher prevalence than all women diagnosed with 
breast cancer in Norway in the early 1970s—well before the 
introduction of mammographic screening in Norway. 
We estimated that an effective screening programme, with 
80% coverage, could have prevented approximately 
2500 deaths in Brazil in 2012, much less than the approximately 
7500 deaths that could have been potentially prevented in the 
same year if 80% of stage III and IV cancers diagnosed in the 
previous 5 years had instead been stage II cancers.
Implications of all the available evidence
Mammographic screening programmes have been established 
in many high-income countries since the late 1980s, when 
findings from the earliest randomised trials were published. 
Since then, national and international advocacy groups have 
been exerting pressure on health systems in low-income and 
middle-income countries to emulate those in high-income 
countries by promoting mammographic screening. Our finding 
of a persistently high proportion of late-stage breast cancer at 
diagnosis in Brazil implies that early detection policies with a 
focus on mammographic screening might have had, so far, 
little effect on mortality from the disease and shows that what 
works in high-income countries does not necessarily work in 
low-income and middle-income countries. Shifting the focus 
of control policies from their current emphasis on 
mammographic screening towards the implementation of 
resource-appropriate approaches for early diagnosis of 
symptomatic disease could potentially prevent a much larger 
number of deaths from the disease than screening for 
asymptomatic disease.
For the ethnoracial 
composition of the Brazilian 
population see https://sidra.
ibge.gov.br/Tabela/3175
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in 20046 have led to a decrease in the prevalence of late-
stage disease at diagnosis across the ethnoracial and 
social strata. Specifically, we aimed to identify patient-
level, tumour-specific, and health system-related 
predictors of late-stage breast cancer at diagnosis; 
examine patterns in the prevalence of late-stage disease 
at diagnosis in Brazil overall and by ethnoracial, social, 
and age group, and compare these estimates with similar 
international data; and consider the implications of the 
findings for early detection policies.
Methods
Study design and participants
In this case-only study, women who had been diagnosed 
with breast cancer in Brazil were identified using a 
nationwide network of hospital-based cancer registries. 
The Brazilian unified health system (Sistema Único de 
Saúde [SUS]) was established by the government in 1988 
to provide universal free access to health care. A network 
of SUS-affiliated hospital-based cancer registries 
(Registros hospitalares de cancer [RHC]) was set up in 
the early 1990s, and an electronic platform for 
standardised collection of data on each patient’s 
sociodemographic characteristics, tumour features, and 
health-care access was adopted in 2000, the data from 
which are collected in the sisRHC database.14 The RHC 
network comprises two different sources: the Integrator 
Module of RHCs coordinated by the Brazilian National 
Cancer Institute, and the RHC of São Paulo state 
coordinated by Fundação Oncocentro of São Paulo 
(FOSP). These two sources use similar pro cedures except 
that the RHC of São Paulo state does not collect data on 
self-reported ethnoracial group, marital status, main 
basis for diagnosis, and centre where patient was first 
seen. Together these two sources comprise health-care 
providers with oncological accreditation located in each 
of the 26 Brazilian states and the Federal District.
The number of health-care providers and the 
proportion that submitted data to RHC varies from year 
to year. RHC comprised approximately 80% of all SUS-
affiliated oncology accredited health-care pro viders in 
Brazil during the study period, although some health-
care providers submitted data only intermittently for 
administrative reasons. However, geographical vari ations 
existed, with RHC covering the highest propor tion of 
health-care providers in the southern region (eg, coverage 
in 2014 was 75% [52 of 69 providers] for the south, 70% 
[seven of ten] for the north, 68% [101 of 148] for the 
southeast, 62% [36 of 58] for the northeast, and 50% [13 
of 26] for the central-west region; Azevedo e Silva G and 
Nogueira MC, unpublished).
Using anonymised electronic individual-level records 
from the sisRHC database, we identified all women 
diagnosed with an invasive breast cancer (ICD-10: C50;15 
data on in-situ tumours were not available), aged 
18–89 years in an SUS-affiliated health-care provider 
during 2001–14. Women with missing information on 
year of diagnosis or on age at diagnosis, and those 
diagnosed at a heath-care provider not affiliated with 
SUS or with unknown affiliation were excluded.
The study was approved by the ethics committee of the 
Instituto de Medicina Social, Universidade Estadual do 
Rio de Janeiro, Brazil, and the ethics committee of the 
London School of Hygiene & Tropical Medicine, London, 
UK. No permissions were needed to access and use data 
from these databases. The study protocol is provided in 
the appendix.
Data extraction 
We extracted individual patient-level, tumour-related, 
and health-care provider data for all eligible women. 
Patient-level data included their ethnoracial group as 
defined by the Brazilian Census (white, black, brown, 
Asian, or Indigenous); educational level (defined as less 
than primary education: ≤4 years of education; primary 
education: 5–9 years of education; secondary education: 
8–12 years of education; and university education: 
>12 years of education); marital status; region of 
residence (each region is formed of smaller Unidades 
Federativas, and the Unidade Federativa of residence of 
a woman coincided with the Unidade Federativa where 
her health-care provider was located for all women); 
migration status (whether a woman had migrated out of 
her region of birth); year of diagnosis; and age at 
diagnosis. Tumour-related data included the stage of 
breast cancer (defined using the TNM Classification of 
Malignant Tumours [TNM]16) at diagnosis, basis for 
diagnosis, histological type of disease, and the presence 
of multiple tumours in the breast or breasts. Health-care 
provider data included type of health-care provider, level 
of SUS oncological accreditation (classified as Unidades 
de Assistência de Alta Complexidade em Oncologia 
[UNACON]: health-care providers with appropriate 
oncological resources to treat the five most common 
cancers in the country, including breast cancer; Centros 
de Alta Complexidade em Oncologia [CACON]: health-
care providers with the necessary multidisciplinary 
resources to treat and manage any type of cancer; and 
other: health-care providers accredited to provide only 
specific oncological services—eg, surgical oncology or 
radiotherapy), type of management (ie, municipal or 
state), and type of service where the patient was first 
seen.
Outcomes
Our objectives were to estimate the prevalence of late-
stage breast cancer at diagnosis overall, across age 
groups, and by ethnoracial and social strata in Brazil 
from 2001 to 2014; to assess the extent to which prevalence 
of late-stage disease at diagnosis was affected by the early 
detection control policies introduced in Brazil in 2004; 
and to compare the prevalence of late-stage disease at 
diagnosis in Brazil with long-term data from high-
income countries from before the introduction of 
See Online for appendix
For the Integrator Module see 
https://irhc.inca.gov.br/RHCNet/
For the RHC of São Paulo state 
see www.fosp.saude.sp.gov.br
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mammographic screening to the most recent post-
screening year for which such data were available. 
Further objectives included estimation of the number 
of deaths that could potentially have been prevented in 
2012 by mammographic screening under different 
scenarios including different levels of coverage and true 
effectiveness, and by downstaging if different propor-
tions of women diagnosed with late-stage disease (TNM 
stage III or IV) in the previous 5 years had instead been 
diagnosed with TMN stage II disease. 
Statistical analysis
The distribution of TNM stage at diagnosis was examined 
overall and by variables related to patient, tumour, and 
health-care provider. We used logistic regression models 
to estimate odds ratios (ORs), with 95% CIs, for late stage 
(TNM stage III–IV) versus early stage (TNM stage I–II) 
breast cancer in relation to patient-related variables, first 
examined separately while con trolling for year of 
diagnosis, age, and region of residence at diagnosis 
(minimally adjusted ORs), and then after further 
adjustment for all other variables (fully adjusted ORs). 
We did analyses overall and separately for the two main 
ethnoracial groups—ie, blacks and browns combined 
and whites. The number of Asian and Indigenous 
women was too small for meaningful stratum-specific 
analyses. Predicted probabilities (ie, predicted prevalence) 
of late-stage disease at diagnosis by edu cational level for 
women who identified as white and as black and brown 
were derived from the fully adjusted models fitted after 
averaging over the distribution of all of the explanatory 
variables other than education and ethnoracial group; we 
calculated SEs for these average predicted prevalences 
using the delta method.
We did all analyses for women of all ages and also 
restricted to the age group targeted by screening. To 
assess the robustness of the overall and stratum-specific 
results, we repeated our analyses on: multiple imputed 
data to address potential biases due to outcome and 
covariate data incompleteness; women who lived in the 
south; and women first diagnosed and treated in the 
health-care provider that submitted the data to RHC (a 
more stringent definition of incidence). We generated 
multiple imputation datasets using a fully conditional 
specification approach under the assumption of missing-
ness at random.17 The imputation model included the 
outcome (stage at diagnosis), the main predictors of 
missingness (age, year of diagnosis, and region of 
residence), and all the variables contributing to the 
analysis models. Together these variables were also the 
main drivers of the variables affected by missingness. 
Missingness was assessed by comparing the distribution 
of all the variables between women with and without 
complete information. Additionally, to increase flexi-
bility, the imputation model included interactions be-
tween year of diagnosis and all other variables. To control 
the Monte Carlo error of estimates and SEs, we generated 
50 imputation sets. Patients from São Paulo state, whose 
registry did not record information on ethnoracial group, 
were excluded from the multiple imputation analyses to 
avoid extrap olation beyond the observed associations.
To compare the observed time trends in the prevalence 
of late-stage disease in Brazil with those from high-
income countries, before and after the intro duction of 
population-based mammo graphic screening, published 
data were extracted from the nationwide cancer registry 
of Norway, one of the few countries where such data have 
been collected.18,19 Population-based mammographic 
screening was introduced gradually in Norway between 
1995 and 2004. The US sur veillance, epidemiology, and 
end results program (SEER) does not use the TNM 
classification;16 however, US tumour stage data, recoded 
according to the TNM classification, separately by age 
and by race, aggregated over the years 1988–2001, have 
been pub lished. The published data are single estimates 
derived by aggregating data for the years 1988–2001 
separately for women who identified as white and black, 
those aged 50–69 years, and all races combined.4 
Opportunistic mammographic screening was introduced 
in the USA in the early 1980s. The reported prevalence 
over time of late-stage disease for these two countries 
were plotted together with the prevalence in our data, 
overall and in strata defined by ethnoracial group, 
educational level, and age. 
We estimated the number of deaths that could have 
been prevented by an effective screening programme for 
Figure 1: Participant selection
*Missing data for one or more patient-level, tumour-level, or health-care 
provider-level variable. 
281 775 women with breast cancer diagnosis 
recorded on sisRHC database
34 056 excluded 
5329 missing year of diagnosis
14 012 diagnosed outside of 2001–14
13 missing age at diagnosis
1281 older than 89 years
27 not invasive cancer
13 394 health-care provider not 
affiliated with SUS or with 
unknown affiliation
247 719 patients diagnosed with invasive breast 
cancer (descriptive analysis)
158 499 excluded 
46 640 stage not 
known
111 859 incomplete 
records*
89 220 included in complete 
records analysis
182 319 included in multiple 
imputation analysis
65 400 excluded as from 
São Paulo state
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women aged 50–69 years in 2012 (the year for which 
mortality data were available in Globocan1) in which 
mortality had been decreased by 20% due to mammo-
graphic screening, as observed in randomised controlled 
trials,20 while assuming different levels of coverage of 
screening (eg, 70%, 80%, 90%) and different true 
effectiveness in 2012. We also estimated the number of 
deaths that could have been potentially prevented in 
Brazil in 2012 by downstaging breast cancer among 
patients diagnosed in the previous 5 years, assuming that 
as low as 50% and as high as 80% of patients with late-
stage disease had been diagnosed at TMN stage II 
instead, which reflects predominantly clinically 
detectable disease. Full details of calculations for number 
of deaths potentially prevented are in the appendix.
Role of the funding source
The funders had no role in study design, data collection, 
data analysis, data interpretation, or writing of the report. 
The corresponding author had full access to all the data 
in the study and had final responsibility for the decision 
to submit for publication.
Results
Between Jan 1, 2001, and Dec 31, 2014, 247 719 women 
aged 18–89 years were diagnosed with an invasive breast 
cancer in SUS-affiliated health-care providers that 
contributed to RHC during this period (figure 1). Mean 
age at diagnosis was 55·4 years (SD 13·3). Of 
247 719 women, 36·2% (n=89 550) were white and 29·8% 
(n=73 826) were black or brown, 35·1% (n=86 920) had no 
or less than primary formal education, and 30·3% 
(n=74 9870) were single, widowed, or divorced at the time 
of diagnosis. Most participants were first seen in a breast 
clinic (40·0%; n=99 024) or oncology service (19·0%; 
n=47 071) and were diagnosed with an invasive ductal 
carcinoma (81·6%; n=202 167). Other individual-level 
demographic, tumour-specific, and health-care provider 
variables are shown in table 1.
Stage at diagnosis was missing for 18·8% (46 640 of 
247 719) of women diagnosed with invasive breast cancer. 
Of 201 079 with a known stage at diagnosis, 39 160 (19·5%) 
had stage I, 81 162 (40·4%) had stage II, 62 118 (30·9%) 
had stage III, and 18 639 (9·3%) had stage IV breast 
cancer. The proportion of women diagnosed with stage I 
disease increased slightly over time, but this increase was 
offset by a similar decrease in the proportion with stage II 
disease (figure 2A). Consequently, the proportion of 
women diagnosed with late-stage (III and IV) disease 
remained relatively constant (approximately 40% of people 
diagnosed per year; table 1) during the study period, except 
for a small decrease in 2011–14 (table 1; figure 2A). Similar 
patterns were observed in analyses restricted to women 
aged 50–69 years, multiple imputation data (all ages) that 
excluded data from São Paulo, and data from São Paulo 
only (figure 2B–D). Information on the extent of the 
primary tumour (the T in TNM classification) was missing 
Early-stage disease 
(TNM stage I or II; 
n=120 322)
Late-stage disease 
(TNM stage III or IV; 
n=80 757)
All stages (including not 
known; n=247 719)
Patient characteristics
Ethnoracial group* 
White 42 966 (63·1%) 25 115 (36·9%) 89 550 (36·2%)
Black 4474 (49·8%) 4519 (50·3%) 11 083 (4·5%)
Brown (Parda) 25 897 (54·4%) 21 689 (45·6%) 62 743 (25·3%)
Asian 639 (54·1%) 542 (45·9%) 1498 (0·6%)
Indigenous 63 (59·4%) 43 (40·6%) 141 (0·1%)
Data missing 46 283 (61·6%) 28 849 (38·4%) 82 704 (33·4%)
Educational level†
None 6216 (49·6%) 6329 (50·5%) 15 828 (6·4%)
Less than primary 34 157 (57·4%) 25 396 (42·6%) 71 092 (28·7%)
Primary 17 990 (60·6%) 11 699 (39·4%) 35 512 (14·3%)
Secondary 19 192 (62·4%) 11 555 (35·6%) 37 001 (14·9%)
University 10 611 (69·5%) 4657 (30·5%) 18 743 (7·6%)
Data missing 32 156 (60·4%) 21 121 (39·6%) 69 543 (28·1%)
Marital status
Married or living as married 38 768 (60·5%) 25 296 (39·5%) 83 783 (33·8%)
Single, widowed, or divorced 31 974 (56·0%) 25 139 (44·0%) 74 987 (30·3%)
Data missing 49 580 (62·1%) 30 322 (38·0%) 88 949 (35·9%)
Migrated out of region of birth
Yes 12 358 (56·5%) 9513 (43·5%) 25 902 (10·5%)
No 100 438 (59·9%) 67 252 (40·1%) 208 184 (84·0%)
Data missing 7526 (65·3%) 3992 (34·7%) 13 633 (5·5%)
Year of diagnosis
2001 4986 (59·1%) 3458 (41·0%) 9425 (3·8%)
2002 6280 (61·5%) 3925 (38·5%) 11 382 (4·6%)
2003 6296 (61·3%) 3971 (38·7%) 11 736 (4·7%)
2004 6816 (60·9%) 4384 (39·1%) 12 891 (5·2%)
2005 7381 (60·5%) 4827 (39·5%) 14 663 (5·9%)
2006 7771 (59·5%) 5301 (40·6%) 15 976 (6·5%)
2007 8816 (60·0%) 5876 (40·0%) 18 257 (7·4%)
2008 9447 (59·0%) 6573 (41·0%) 20 314 (8·2%)
2009 9963 (58·9%) 6962 (41·1%) 21 522 (8·7%)
2010 10 039 (57·9%) 7316 (42·2%) 21 122 (8·9%)
2011 10 693 (58·6%) 7551 (41·4%) 23 328 (9·4%)
2012 10 959 (59·7%) 7400 (40·3%) 23 326 (9·4%)
2013 11 451 (60·8%) 7395 (39·2%) 23 577 (9·5%)
2014 9424 (61·8%) 5818 (38·2%) 19 200 (7·8%)
Age at diagnosis, years
18–39 11 365 (50·9%) 10 978 (49·1%) 27 407 (11·1%)
40–49 30 187 (59·0%) 20 982 (38·9%) 62 910 (25·4%)
50–59 32 957 (61·1%) 20 982 (38·9%) 66 295 (26·8%)
60–69 25 772 (63·4%) 14 905 (36·6%) 50 072 (20·2%)
70–89 20 041 (60·8%) 12 909 (39·2%) 41 035 (16·6%)
Region of residence at diagnosis
North 2895 (51·4%) 2743 (48·7%) 8001 (3·2%)
Northeast 24 195 (55·5%) 19 371 (44·5%) 58 410 (23·6%)
Central west 2256 (52·5%) 2043 (47·5%) 8542 (3·5%)
Southeast 65 702 (60·5%) 42 902 (39·5%) 120 516 (48·7%)
South 25 274 (64·9%) 13 698 (35·2%) 52 250 (21·1%)
(Table 1 continues on next page)
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for 69 535 (28·1%) women, but, among those with this 
informa tion, tumour size at diagnosis was 2 cm or smaller 
for 26·8% (47 698 of 178 184), larger than 2 cm for 53·9% 
(95 982; including >5 cm for 15·5% [27 648]), and of 
any size but with extension to the skin or chest wall for 
19·4% (34 504). Among women aged 50–69 years, 
29·6% (25 102 of 84 027) had a tumour of 2 cm or smaller, 
51·5% (43 282) had a tumour larger than 2 cm (includ-
ing 13·4% [11 290] with a tumour >5 cm), and 18·6% 
(15 643) had a tumour of any size that extended to the skin 
or chest wall.
Because of missing covariate data, and notably because 
of a lack of collection of data on ethnoracial group, and 
marital status by health-care providers in São Paulo state, 
complete records were only available for 89 220 (36·0%) 
of 247 719 women (figure 1). The proportion of women 
with incomplete records (ie, data missing for at least one 
variable) varied according to age, year of diagnosis, and 
region at diagnosis (appendix). However, we saw little 
evidence of variation in the size of the associations 
between variables that were not affected by missingness 
(ie, age, year of diagnosis, region of diagnosis) and late-
stage cancer at diagnosis, when estimated using all 
records with known stage of disease in subsets with 
complete and incomplete records for the other variables, 
and among the subset with incomplete records between 
those diagnosed and not diagnosed in São Paulo state 
(appendix).
Analyses into the association of patient ethnoracial and 
social characteristics with late-stage cancer at diagnosis 
yielded similar findings when minimally adjusted and 
fully adjusted models were fitted using data from women 
with complete records, indicating that mutual adjustment 
did not have a substantial effect on the estimates (table 2). 
The odds of late-stage cancer at diagnosis was higher for 
women who identified as black (minimally adjusted 
OR 1·61, 95% CI 1·53–1·70; fully adjusted OR 1·45, 
1·38–1·54), brown (minimally adjusted OR 1·26, 95% CI 
1·22–1·30; fully adjusted OR 1·18, 1·14–1·23), and Asian 
(minimally adjusted 1·29, 95% CI 1·13–1·48; fully 
adjusted OR 1·18, 1·03–1·36) than for those who 
identified as white, but not for women who identified as 
indigenous (although the estimates for this group had 
wide 95% CIs due to small numbers; table 2). Late-stage 
cancer at diagnosis was inversely associated with 
educational level (p value for linear trend <0·0001), with 
women who attended university having a fully adjusted 
OR of 0·41 (95% CI 0·38–0·44) compared with those 
who had no formal education. Single, widowed, or 
divorced women also had a higher odds of late-stage 
disease at diagnosis than women who were married or 
living as married (fully adjusted OR 1·23, 95% CI 
1·19–1·26), as did women who had emigrated out of 
their region of birth than those who did not (fully 
adjusted OR 1·09, 1·03–1·15; table 2).
Similar findings were yielded when these complete-
records analyses were restricted to patients diagnosed at 
age 50–69 years (appendix), those living in the south, and 
those who were first diagnosed and treated in the same 
health-care provider that submitted the data to RHC 
(appendix). Similar results were also obtained when 
analyses accounted for missing data via multiple 
imputation (table 2). The inverse trend in the odds of 
Early-stage disease 
(TNM stage I or II; 
n=120 322)
Late-stage disease 
(TNM stage III or IV; 
n=80 757)
All stages (including not 
known; n=247 719)
(Continued from previous page)
Tumour characteristics
Main basis for diagnosis‡
Histology 76 721 (58·8%) 53 728 (41·2%) 172 478 (69·6%)
Other microscopic 
procedures
2246 (62·6%) 1341 (37·4%) 4918 (2·0%)
Clinical examination 1614 (54·7%) 1337 (45·3%) 3947 (1·6%)
Data missing 39 741 (62·0%) 24 351 (38·0%) 66 376 (26·8%)
Histological type§
Invasive ductal carcinoma 98 408 (59·5%) 67 025 (40·5%) 202 167 (81·6%)
Invasive lobular carcinoma 6898 (61·0%) 4416 (39·0%) 13 491 (5·5%)
Other 15 005 (61·8%) 9291 (38·2%) 31 946 (12·9%)
Data missing 11 (30·6%) 25 (69·4%) 115 (0·1%)
Presence of multiple tumours in breast or breasts
Yes or possible 2997 (60·3%) 1972 (39·7%) 6492 (2·6%)
No 74 180 (58·6%) 52 519 (41·5%) 168 180 (67·9%)
Data missing 43 145 (62·2%) 26 266 (37·8%) 73 047 (29·5%)
Health-care provider related variables
Type of health-care provider
General hospital 60 993 (61·6%) 37 958 (38·4%) 128 164 (51·7%)
Specialised hospital 57 196 (58·3%) 40 986 (41·7%) 115 458 (46·6%)
Other¶ 2133 (54·1%) 1813 (46·0%) 4097 (1·7%)
Level of SUS oncological accreditation
CACON 54 219 (59·2%) 37 374 (40·8%) 108 184 (43·7%)
UNACON 63 860 (60·3%) 42 128 (39·8%) 134 981 (54·5%)
Other 496 (61·8%) 307 (38·2%) 1531 (0·6%)
Not known 1747 (64·8%) 948 (35·2%) 3023 (1·2%)
Type of management
Municipal 60 997 (60·4%) 40 075 (39·7%) 129 986 (52·5%)
State 37 406 (58·6%) 26 454 (41·4%) 72 589 (29·3%)
Both 21 919 (60·6%) 14 228 (39·4%) 45 144 (18·2%)
Service where patient was first seen
Breast clinic 46 437 (59·4%) 31 735 (40·6%) 99 024 (40·0%)
Oncology 19 029 (54·5%) 15 919 (45·6%) 47 071 (19·0%)
Radiotherapy 6812 (66·9%) 3373 (33·1%) 13 473 (5·4%)
Other|| 3960 (57·5%) 2925 (42·5%) 12 088 (4·9%)
Data missing 44 084 (62·2%) 26 805 (37·8%) 76 063 (30·7%)
Data are n (%), with proportions in the early stage and late stage disease columns using the total number with that 
characteristic as the denominator, and in the total column using the total population as the denominator. 
SUS=Sistema Único de Saúde (Brazilian national public health service). CACON=Centros de Alta Complexidade em 
Oncologia. UNACON=Unidades de Assistência de Alta Complexidade em Oncologia. *Based on self-reported 
ethnoracial group classified according to the Brazilian Census. †Number of years of formal education: less than primary 
education ≤4 years; primary education 5–9 years; secondary education 8–12 years; university >12 years. ‡Most 
important basis for breast cancer diagnosis. §Histological type classified according to the International Classification of 
Diseases for Oncology.14 ¶Includes stand-alone specialised clinics. ||Includes, among others, general surgery, 
gynaecology, and mammographic screening units.
Table 1: Characteristics of the participants, overall and by stage at diagnosis
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diagnosis with late-stage disease with increasing 
educational level, and the positive associations with 
being single, widowed, or divorced, and having emigrated 
out of the region of birth, were similar among people 
who identified as white and those who identified as black 
and brown, for both complete record and multiple 
imputation analyses (table 2).
The odds of late-stage cancer at diagnosis, after 
adjustment for year of diagnosis and age (minimal 
adjustment), was highest in the north and lowest in the 
south of the country, both overall and when analysed 
separately for people who identified as white and black 
and brown combined, and for complete records and 
multiple imputation analyses (table 3). There was 
evidence of a significant difference in the magnitude of 
the ORs for region of residence at diagnosis between the 
two ethnoracial groups (pinteraction<0·0001 in the complete 
records analysis; pinteraction=0·0030 for multiple imputation 
analysis), with women who identi fied as black and brown 
having greater odds of late-stage cancer at diagnosis than 
those who identified as white in the north of the country 
(table 3). As expected, the odds of late-stage cancer at 
diagnosis was higher among younger women, for whom 
the disease is most aggressive, than among older women, 
even after adjustment for region and year of diagnosis 
(table 3). We saw a pattern towards women who identified 
as black or brown having a decreased odds of late-stage 
cancer at diagnosis with later year of diagnosis compared 
with women who identified as white (pinteraction<0·0001 for 
complete records analysis; pinteraction=0·0007 for multiple 
imputation analysis). However, this interaction was 
driven by differences in the last and first year (when the 
analyses were restricted to 2002–13 pinteraction=0·16 for 
complete records analysis and pinteraction=0·35 for multiple 
imputation analysis; table 3).
Figure 3A shows the predicted prevalence of late-stage 
cancer at diagnosis for each education level, separately for 
women who identified as whites and those who identified 
as black and brown combined. In our analysis of women 
with complete records, across all ages and regions, we 
found an almost 20% absolute difference between the 
group with the highest predicted prevalence of late-stage 
cancer at diagnosis—black and brown women with no or 
less than primary education (48·8%, 95% CI 48·2–49·5)—
and the group with the lowest predicted probability—
white women with a university education (29·4%, 
28·2–30·6; figure 3A). We saw a similar pattern in 
multiple imputation analysis of all ages in all regions, and 
in analyses restricted to those aged 50–69 years and those 
in the south of the country (figure 3B–D).
Figure 2: Breast cancer stage at diagnosis for all patients with known stage of all ages (A), those aged 50–69 years (B), from multiple imputation analysis (C), 
and in São Paulo of all ages (D), Brazil, 2001–14
Data from São Paulo state are not included in the multiple imputation analysis.
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The overall prevalence of late-stage cancer at dia-
gnosis remained high, at approximately 40%, in Brazil 
through out 2001–14, although we observed a slight 
decrease since 2011 (figure 4). Nevertheless, the overall 
prevalence of late-stage disease at diagnosis in Brazil 
was more than twice that in Norway (16·3% [1043 of 
6385; 95% CI 15·4–17·2] of women diagnosed with 
invasive breast cancer in 1970–74), well before the 
introduction of mammographic screening in Norway 
(figure 4). Even among the most privileged women in 
Brazil—ie, university educated white women—
prevalence of late-stage cancer at diagnosis in 2014 
was still considerably higher than among all women 
diagnosed with breast cancer in Norway in the early 
1970s and among white and black women diagnosed 
in the USA in 1988–2001 (ie, after introduction of 
opportunistic screening in the USA; presented at a 
single timepoints in the middle of this period). Similar 
differences in the prevalence of late-stage cancer at 
diagnosis between Brazil and high-income countries 
emerged when analyses were restricted to women aged 
50–69 years (figure 4).
Mortality due to breast cancer has increased across all 
age groups since 1979 in Brazil, contrasting substantially 
with the decreases seen in most high-income countries, 
including in Norway and the USA (appendix). The 
number of breast cancer deaths that might have been 
prevented in Brazil in 2012 by mammographic screening, 
assuming 80% coverage, appropriate follow-up, and 
manage ment of abnormalities suspected to be cancerous, 
is approximately 2500 (appendix). Results for different 
screening coverages and true effectiveness scenarios are 
shown in the appendix. The number of breast cancer 
deaths that might have been prevented in 2012 if as many 
as 80% of all women diagnosed at stage III and IV in the 
previous 5 years had instead been diagnosed with stage II 
disease is approximately 7500. If this proportion had been 
as low as 50% of all women diagnosed at stage III and IV, 
approximately 4700 deaths might have been prevented 
(appendix).
Discussion
In this study we showed that approximately 40% of 
women with breast cancer in Brazil were diagnosed at 
Figure 3: Estimated average prevalence of late-stage breast cancer at diagnosis in white women and black and brown women combined, by educational level
(A) All regions and all ages, (C) all regions for those aged 50–69 years, and (D) in south Brazil for all ages as yielded by complete records analyses; and (B) for all regions 
and all ages by multiple imputation analyses. Data are average prevalence, with 95% CI in parentheses. Data from São Paulo state are not included in any of these 
analyses. Vertical dashed lines in panels A, B, and C indicate the observed average prevalence of late-stage disease at diagnosis in the complete records subset 
(n=88 269; 41·7%), and in panel B this line indicates the average prevalence of late-stage cancer at diagnosis from multiple imputed data (n=183 319; 41·3%).
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an advanced stage in 2001–14, a stage at which treatment 
options are more restricted and less effective and, hence, 
survival is poorer than at at earlier stages. The proportion 
of women diagnosed with advanced disease, overall and 
at the ages targeted by screening, remained high 
throughout the study period, although with a slight 
decrease since 2011, despite the introduction of early 
detection policies in 2004.6 We also identified persistently 
notable ethnoracial and social disparities, with the 
prevalence of late-stage cancer diagnoses being highest 
in women who identified as black and brown who had 
little or no formal education and lowest in women who 
were university educated and identified as white. 
Nevertheless, the predicted prevalence of late-stage 
disease among university educated white women 
diagnosed with breast cancer was still considerably 
higher than among all women diagnosed with cancer in 
Norway in 1970–74, well before the introduction of 
population-based mammographic screening in this 
country, and among white and black women in the USA 
in 1988–2001. Consistent with studies in sub-Saharan 
Africa21 and in the USA,22 single, widowed, or divorced 
women were more likely to be diagnosed at a late-stage of 
disease independent of their ethnoracial group or 
educational level. Having emigrated from their region of 
birth was also found to be independently associated with 
increased risks of late-stage disease at diagnosis.
Our study benefited from a large number of women 
with breast cancer who were identified through a 
nationwide network of SUS-affiliated health-care 
providers in Brazil, which covered approximately 80% of 
all oncology accredited health-care providers in the 
public system. A limitation of our study is the lack of 
data collected on in-situ tumours. Although over 
20 population-based cancer registries exist in Brazil, 
covering predominantly urban areas, they do not collect 
information on tumour stage. Additionally, for logistic 
reasons, some health-care providers contribute data to 
RHC only intermittently. However, analysis restricted 
to the south of Brazil, the region with the highest 
RHC coverage, yielded ethnoracial differences in the 
prevalence of late-stage breast cancer at diagnosis. Some 
women (eg, poor women living in remote areas) might 
have died from breast cancer without having ever 
contacted a health-care provider where a definitive 
diagnosis of the disease could be made. Such women 
could not be captured by the RHC network, but their 
exclusion from our analysis would have led, if anything, 
to an underestimation of the prevalence of diagnosis of 
late-stage disease. Never theless, the observed prevalence 
of late-stage disease at diagnosis is consistent with that 
reported by a Brazilian multicentre retrospective study of 
3142 women with breast cancer.5 Self-reported ethnoracial 
group is prone to mis classification but a good overall 
agreement with genomic ancestry was found by a study 
in Brazil.23 Outcome and covariate data were missing for 
various subgroups of women, particularly from São Paulo 
state. Reassuringly, our findings were robust across the 
various subsets of women examined and in multiple 
imputation analyses, although the results from the 
multiple imputation analysis were conditional on the 
assumption that the variables included in the imputation 
step were sufficient to render missing ness at random. If 
this assumption was untrue, selection bias would affect 
the results. However, the multiple imputation analyses 
included the most important drivers of missingness in 
this sisRHC administrative dataset (ie, age, year of 
diagnosis, and region of residence at diagnosis).
The persistently high prevalence of late-stage breast 
cancer at diagnosis at all ages and at ages targeted by 
screening indicates that early detection policies, includ ing 
mammographic screening, are likely to have had, so far, 
little effect on mortality from this disease, and is consistent 
with the continuing rise in breast cancer mortality in 
Brazil.2 Late-stage breast cancer at diagnosis might be 
the result of an aggressive fast-growing tumour or the 
consequence of long delays between symptom onset and 
diagnosis. RHC does not collect data on markers of 
tumour aggressiveness but some studies24,25 have shown 
that the receptor subtype distribution in Brazil is broadly 
similar to that found in high-income countries.26 The 
frequency of more aggressive molecular subtypes 
(eg, hormone-receptor-negative breast cancer) is higher in 
the USA among black women than white women,8,27,28 but 
no similar differences in the distribution of tumour 
subtypes between black and white women has been 
observed in Brazil.24,25 Furthermore, the large educational 
Figure 4: Prevalence of late-stage breast cancer at diagnosis in Brazil, 2001–14; in Norway, 1970–2010; and in 
the USA, 1988–2001, before and after introduction of mammographic screening
Data for Brazil are for the whole country and selected population groups from 2001–14. Mammographic screening 
is population based in Norway and opportunistic in Brazil and the USA. For Norway, year of diagnosis in the 
published data was categorised as 1970–74, 1975–79, 1980–84, 1985–89, 1987–95, 1996–2004, and 2005–10; 
hence, estimates were plotted at the midpoint of each interval (eg, at 1972 for 1970–74 and at 2007·5 for 2005–10). 
Similarly, the estimates for the USA are aggregates for the whole time period. The US point estimates are for a time 
period after the introduction of opportunistic mammographic screening. Age specific data on stage of breast cancer 
at diagnosis by race were not provided in the US sur veillance, epidemiology, and end results report.4
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gradient observed in both white women and black and 
brown women in our study is consistent with ethnoracial 
differences in late-stage cancer at diagnosis being mainly 
driven by social rather than biological factors. Ethnoracial 
disparities in health-care access,29–31 including access to 
mammographic screening,32 have been observed in Brazil 
to be driven by discrimination and lack of support policies 
for women who are black or brown.33–35
Delays from symptom recognition to diagnosis of 
3 months or longer are associated with later stage at 
presentation and poorer survival than earlier diagnoses.36 
In high-income countries, the time interval from 
symptom recognition to a diagnosis is usually less than 
30 days,37,38 but this interval appears to be much longer in 
Brazil (median of about 7–8 months).9 Tumour size 
distribution in our study is consistent with pronounced 
delays in diagnosis after a tumour is palpable and, hence, 
clinically sympto matic. Only 27% of women in our study 
had invasive tumours that were 2 cm or smaller and 15% 
were larger than 5 cm. By contrast, 65·9% of women 
with invasive tumours in the USA in 1988–2001 were 
2·2 cm or smaller, and 5·8% were larger than 5·2 cm at 
diagnosis.4 A tumour growth model39 has predicted that, 
on average, a tumour of 2 cm (the average size when a 
tumour first becomes clinically palpable) takes 12 months 
to double in size, and 24 months to reach 6 cm in size. 
Although such models rely on several assumptions (eg, 
breast cancer subtype distribution and biology being 
similar to those in high-income countries),39 they indicate 
that the distribution of tumour size in Brazil is consistent 
with long delays in diagnosis after symptom onset.
In high-income countries, mammographic screening 
was introduced at a time when symptomatic disease had 
already been successfully downstaged, as illustrated by 
historical data from Norway where the prevalence of late-
stage disease at diagnosis was only around 15% in 
1970–74—ie, at a time when the health system was able to 
appropriately manage symptomatic disease and could 
thus cope with the additional burden of screen-detected 
asymptomatic cases. In Brazil, as in many other low-
income and middle-income countries,40 early detection 
policies have focused mainly on mammographic 
screening6 despite weak health systems. Consequently 
implementa tion is opportunistic rather than population 
based, with coverage in the target age group for SUS-
affiliated women (ranging from 27%, based on SUS data,41 
to 51%, based on self-reports in a Brazilian National 
Health Survey for 201342) well below the 70% minimum 
coverage for a programme to be effective,43 and poor 
follow-up of screened women with radiological findings 
suspected to be cancerous (27% for women aged 
50–59 years and 63% for those aged 60–69 years in 2010 
based on SUS data41), indicating poor effectiveness. At the 
same time, resources are being diverted to screen women 
outside the target age group, particularly those younger 
than 50 years.41 In high-income countries, the introduction 
of organised mammographic screening has led to a 
substantial increase in the proportion of small (in situ and 
stage I) tumours being diagnosed and a concomitant 
decrease in the proportion of large tumours.44,45 Data on 
in-situ tumours were not available in our study, but the 
proportion of stage I tumours increased only modestly in 
the age group targeted for screening throughout the study 
period, in line with the programme having low coverage.
We estimate that about 7500 deaths due to breast 
cancer might have been prevented in Brazil in 2012 if 
80% of women with breast cancer who had been 
diagnosed at stage III or IV in the previous 5 years had 
instead been diagnosed with stage II disease. By contrast, 
mammo graphic screening, assuming an 80% coverage 
and appropriate follow-up of radiologically suspicious 
abnormalities might have prevented approximately 
2500 deaths in 2012. Although these estimates are based 
on many assumptions, and far from ideal estimates of 
breast cancer incidence, mortality, and survival (eg, no 
availability of national stage-specific survival estimates 
overall or by ethnoracial stratum), they highlight the 
potential benefit of investing in downstaging relative to 
screening. Notably, 53·0% of all women diagnosed with 
invasive breast cancer during the study period, 
corresponding to 55·6% of those diagnosed at stages III 
and IV, were diagnosed outside the screening target age 
group (ie, 50–69 years). Even in countries with a high-
coverage population-based screening programme, most 
women with breast cancer present symptomatically 
(eg, in the UK in 2007, only 32% of all breast cancers, and 
56% in the targeted age group of 50–69 years, were 
detected via screening).46
With the incidence of breast cancer in Brazil projected to 
almost double by 2035,1 timely diagnosis of symptomatic 
disease will be key to decreasing mortality due to the 
disease. Although the 2018 Brazilian Government 
guidelines47 put an emphasis on mammographic 
screening, they also highlight the need for early diagnosis 
of women who are symptomatic.47 The findings from our 
study indicate that priority should be given to women who 
are symptomatic by implementing resource-appropriate 
strategies to ensure timely access to diagnosis and 
treatment, particularly among those who are disadvantaged. 
Implementation of effective population-based screening 
programmes requires a strong health system that is able to 
appropriately manage symptomatic disease and the 
capability to provide access to high-quality mammography, 
high coverage of the target population, timely access for 
women with screen-detected abnormalities suspected 
to be cancerous to appropriate diagnostic and treatment 
services, and comprehensive built-in quality assurance 
mechanisms. The findings from this study show that even 
an upper-middle-income country such as Brazil, which 
provides universal free access to health care, struggles to 
achieve these requirements.
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